Indeed, preclinical research investigating such dual DDR inhibition approaches outside of glioblastoma research is supportive of this concept, for example CHK1 and PARP1 inhibition in pancreatic cancer [184], CHK2 and PARP1 inhibition in lymphoma [185], CHK1 and PARP1 inhibition in breast cancer [186], ATR and PARP1 inhibition in breast and ovarian cancer [187], and ATM and PARP1 inhibition in lung cancer [188]. This evidence concerns the gene PARP1 and familial pancreatic carcinoma.